Waylivra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis of rare lipid disorders, advancements in antisense oligonucleotide development, expansion of specialty lipid clinics, increased awareness of pancreatitis risks, availability of orphan drug incentives.

The growth in the forecast period can be attributed to increasing investments in genetic medicine research, rising adoption of targeted metabolic therapies, expansion of personalized lipid management approaches, growing focus on rare disease treatment accessibility, increasing integration of genomic diagnostics. Major trends in the forecast period include increasing adoption of rna-targeted therapies, rising focus on rare lipid disorder management, growing use of precision metabolic treatments, expansion of genetic disorder screening programs, enhanced monitoring of lipid metabolism outcomes.

The rising prevalence of rare genetic disorders is expected to drive the growth of the waylivra market in the coming years. Rare genetic disorders are conditions caused by mutations in an individual's DNA, impacting a significant number of people. This increase in prevalence is attributed to advancements in genetic testing, greater awareness, improved reporting, and expanded access to genetic screening and reproductive technologies. Waylivra treats rare genetic disorders by blocking a protein involved in lipid metabolism, which helps lower blood lipid levels. For example, according to the National Health Service, a UK-based government department, in May 2024 approximately 17,000 people in England live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. Therefore, the increasing prevalence of rare genetic disorders is driving the waylivra market.

The growth in healthcare expenditure is also expected to support the expansion of the waylivra market. Healthcare expenditure includes financial resources allocated to medical services, covering treatments, hospital care, pharmaceuticals, healthcare infrastructure, and preventive care. The rise in spending is driven by higher demand for advanced medical treatments, an aging population, and the growing prevalence of chronic diseases. Increased healthcare expenditure supports the waylivra market by driving demand for innovative healthcare technologies that enhance patient care and improve operational efficiency as providers invest in advanced solutions. For instance, according to the UK’s Office for National Statistics, provisional estimates for April 2025 show that UK healthcare spending reached £317 billion in 2024, growing 6.5% in nominal terms and 2.4% in real terms from 2023. Total long-term care expenditure also rose 3.1% in real terms in 2023, primarily due to increased government spending. Consequently, rising healthcare expenditure is contributing to the growth of the waylivra market.

In January 2024, Acino International AG, a Switzerland-based pharmaceutical company, partnered with Sobi in an exclusive distribution agreement to commercialize several orphan drugs, including doptelet, aspaveli, gamifant, kineret, orfadin, tegsedi, and waylivra in Kazakhstan. Under the agreement, Acino will handle marketing and commercialization of Sobi’s products within the specialized hospital segment starting in early 2024. Sobi is a Sweden-based biopharmaceutical company.

Major companies operating in the waylivra market are Akcea Therapeutics Inc.

Europe was the largest region in the waylivra market in 2025. The regions covered in the waylivra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the waylivra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the waylivra market by increasing costs of imported active pharmaceutical ingredients, nucleic acid-based compounds, specialized formulation materials, and cold-chain distribution services. Specialty treatment centers in North America and Europe are most affected due to dependence on global sourcing of advanced RNA therapeutics, while Asia-Pacific faces higher costs in scaling rare disease drug access. These tariffs are contributing to higher therapy prices and supply chain complexity. However, they are also encouraging regional manufacturing of RNA-based drugs, localized formulation capabilities, and stronger domestic supply chains for rare disease therapeutics.

The waylivra market research report is one of a series of new reports that provides waylivra market statistics, including waylivra industry global market size, regional shares, competitors with a waylivra market share, detailed waylivra market segments, market trends and opportunities, and any further data you may need to thrive in the waylivra industry. This waylivra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Waylivra (volanesorsen) is a medication indicated for a rare genetic disorder marked by extremely high triglyceride levels. It works by blocking the production of ApoC-III, a protein that regulates triglyceride metabolism, thereby lowering triglyceride levels and reducing the risk of complications such as pancreatitis.

The primary indications for Waylivra include familial chylomicronemia syndrome, hypertriglyceridemia, and other rare lipid disorders. Familial chylomicronemia syndrome (FCS) is a rare genetic condition characterized by very high triglyceride levels in the blood, increasing the risk of pancreatitis and other health issues. Waylivra is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by various patient groups, including adults and elderly patients.

The waylivra market consists of sales of syringes, injection supplies, and patient support programs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.